Dianthus Therapeutics, Inc. /DE/ (DNTH) is a biotechnology company committed to advancing the field of healthcare through groundbreaking scientific research and innovations. Founded with the mission to foster the development of new therapeutics for various diseases, the company's work is chiefly focused on discovering and developing advanced, first-in-class drugs that can offer better treatment options.
Dianthus operates within the pharma industry's highly competitive and rapidly changing landscape, constantly pushing boundaries to deliver medicines that can make a significant difference in patients' lives. Although the company is relatively young, its team comprises accomplished scientists, researchers, and industry stalwarts who bring a wealth of experience to the table.
One of Dianthus’ core strengths lies in its advanced research and development capabilities. The company has developed a unique and proprietary platform that accelerates the drug discovery and development process. This platform empowers DNTH to create novel therapeutics that target a range of diseases that are currently inadequately addressed by existing treatments.
As a testament to its innovative endeavors, DNTH has an impressive portfolio of potential therapeutic compounds in the pipeline. These drugs-in-development primarily focus on high-burden diseases, aiming to create a transformative impact on global health.
The corporate philosophy of Dianthus hinges on the principles of integrity, accountability, and transparency. The company endeavors to uphold ethical practices in research and development, ensuring that its operations align with regulatory standards.
It is worth mentioning that Dianthus Therapeutics, Inc. /DE/ (DNTH) places a strong emphasis on collaborations. It works closely with a network of experts, research institutions, and other biopharma firms to facilitate knowledge sharing and technical cooperation. This collaborative approach enables the company to drive rapid and robust development in its drug-discovery process.
In essence, Dianthus Therapeutics' commitment to creating a healthier future through innovative therapies establishes it as a forward-looking player in the biopharma industry. With its potent blend of advanced technology, a strong pipeline of promising drugs, and an expert team, Dianthus is poised to make a considerable impact in the complex world of drug discovery and development, thereby revolutionizing the treatment of various health conditions.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Bank of America Corp DE has acquired a new position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH), purchasing 256,833 shares valued at approximately $25 million, representing a 0.47% stake in the company. Despite institutional ownership of 47.53% and a "Moderate Buy" consensus rating from analysts, DNTH shares recently fell by 5.0% after the company reported a quarterly loss that missed consensus estimates. Over the past 90 days, company insiders have sold a significant amount of shares totaling $29.3 million.
Engineers Gate Manager LP significantly reduced its stake in Dianthus Therapeutics (NASDAQ:DNTH) by 47.1% in Q2 2026, selling 10,330 shares. Despite this reduction, institutional investors collectively own 47.53% of the company. Dianthus Therapeutics shares opened down 4.3% at $96.81, and the company reported a quarterly loss of $0.90 per share, missing analyst estimates, though revenue exceeded expectations.
_07_03_2026_03_50_21_133108.jpg)
Randhawa Simrat, Executive Vice President and Head of Research and Development at Dianthus Therapeutics, exercised options for 23,124 shares on September 1, 2026. Following the exercise, Simrat sold all 23,124 shares, with sale prices ranging from $105.19 to $106.74 per share. After these transactions, Simrat retained 4,000 shares and holds 87,500 derivative securities.
Citi has initiated a Buy rating on Dianthus Therapeutics (DNTH), citing a multibillion-dollar sales potential for its lead drug, claseprubart. Dianthus is a biotech company focused on developing treatments for autoimmune conditions. The analyst's positive outlook is based on the significant market opportunity for the complement inhibitor.
Dianthus Therapeutics (DNTH) shares have surged 88.9% in the past six months, driven by investor confidence in its lead asset, claseprubart, and a strong financial position. The company is advancing claseprubart for multiple autoimmune diseases, with pivotal phase III trials underway or planned for gMG and CIDP. Additionally, Dianthus's second pipeline candidate, DNTH212, is progressing through phase I studies for several autoimmune disorders, supported by a robust cash reserve of $1.2 billion.
Royal Bank of Canada significantly increased its stake in Dianthus Therapeutics, Inc. by 847.5% in the first quarter, now holding 19,064 shares valued at $1.60 million. Despite the company missing EPS estimates, institutional investors collectively own 47.53% of the stock, and Wall Street analysts maintain a "Moderate Buy" rating with an average price target of $124.27. However, recent insider selling, including by the CEO and a director, totals approximately $29.6 million over the past 90 days.
Eagle Health Investments LP has acquired 131,344 shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) valued at approximately $12.8 million, making it their 20th largest holding. Despite this institutional interest and a "Moderate Buy" consensus rating from analysts, insiders have recently sold a significant amount of stock, totaling nearly $29.6 million. Dianthus Therapeutics reported a quarterly loss but exceeded revenue expectations, and the company is developing complement therapeutics for autoimmune and inflammatory diseases.
Handelsbanken Fonder AB has initiated a $1.49 million position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) during the second quarter of 2026. This investment comes as institutional investors collectively own 47.53% of the company, and analysts maintain a "Moderate Buy" consensus rating with an average price target of $124.27, despite the company missing its quarterly EPS estimates and recent insider stock sales.